Trevena, Inc. (TRVN)

Targeted and Innovative CNS Therapies

Trevena’s novel pipeline is based on Nobel Prize winning research and includes one FDA-approved product in the United States, OLINVYK™ (oliceridine) injection, and four differentiated investigational drug candidates. All of the company’s assets are new chemical entities with unique mechanisms of action being developed for areas of critical need in central nervous system (CNS) and other disorders.

Program	Molecular Target	Therapeutic Target	Current Phase	PC	PH1	PH2	PH3	NDA	Approved
OLINVYK™ (oliceridine) injection	Mu receptor	Acute pain	Approved	Intravenous PC complete	PH1 complete	PH2 complete	PH3 complete	NDA complete	Approved in progress
TRV027	AT₁ receptor	ARDS / abnormal clotting (COVID-19)	PH2	Intravenous PC complete	PH1 complete	PH2 in progress	PH3 not started	NDA not started	Approved not started
TRV250	Delta receptor	Acute migraine	PH1	Oral/Subcutaneous PC complete	PH1 in progress	PH2 not started	PH3 not started	NDA not started	Approved not started
TRV734	Mu receptor	Opioid use disorder	PH1	Oral PC complete	PH1 in progress	PH2 not started	PH3 not started	NDA not started	Approved not started
TRV045	S1P receptor	Diabetic neuropathic pain	PC	Oral PC in progress	PH1 not started	PH2 not started	PH3 not started	NDA not started	Approved not started

Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. The pipeline assets are investigational products not approved by FDA for sale or distribution in the U.S.